119-hr4605

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4605 Introduced in House

    (IH) ]

<DOC>

119th CONGRESS
 1st Session
 H. R. 4605

 To ban drug manufacturers from using direct-to-consumer advertising, 
 including social media, to promote their products.

_______________________________________________________________________

 IN THE HOUSE OF REPRESENTATIVES

 July 22, 2025

Mr. Nadler (for himself and Ms. Dexter) introduced the following bill; 
 which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

 A BILL

 To ban drug manufacturers from using direct-to-consumer advertising, 
 including social media, to promote their products.

 Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

 This Act may be cited as the ``End Prescription Drug Ads Now Act''.

SEC. 2. PROHIBITION ON DIRECT-TO-CONSUMER DRUG ADVERTISING OF DRUGS.

    (a) In General.--

Section 502 the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 352) is amended by adding at the end the following:
 ``

    (hh)

    (1) If it is a drug approved under 

section 505 or licensed 
under 

section 351 of the Public Health Service Act, and subject to 

section 503

    (b)

    (1) , and the holder of the approved application under 

section 505 or of the license under such 

section 351 has conducted 
direct-to-consumer advertising of the drug within the most recent 30-
day period.
 ``

    (2) For purposes of this paragraph, the term `direct-to-consumer 
advertising', with respect to a drug subject to 

section 503

    (b)

    (1) , 
means any promotional communication targeting consumers, including 
through television, radio, print media, digital platforms, and social 
media, for purposes of marketing such a drug.''.

    (b) Effective Date.--The amendment made by subsection

    (a) shall 
take effect 30 days after the date of enactment of this Act, and shall 
apply with respect to any drug approved under 

section 505 of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or licensed under 

section 351 of the Public Health Service Act (42 U.S.C. 262), 
regardless of when the drug was approved or licensed.
 <all>